Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

Inclusion Criteria:

• Participant must be a boy or girl, aged from birth (0 months) to less than (<) 18years at screening. Participants in Cohort 4 who are <6 months of age at screening,gestational age at birth had to be greater than or equal to (>=) 37 weeks

• Participant must weigh >3 kilogram (kg) at baseline and be within the 5th and 95thpercentiles (inclusive) for the participant's age, based on the World HealthOrganization (WHO) child growth standards; Body Mass Index (BMI) for age. In Cohorts 3 and 4, weight for height/length may be used instead of BMI for age according tothe local standard of care. Per WHO guidance, for participants aged < 2 years inCohort 4, length will be used to calculate the BMI instead of height

• For Cohorts 1 and 2 only: Heterosexually active girls may participate if they are ofnon-childbearing potential, or if they are using effective birth control methods andare willing to continue practicing birth control methods throughout MultidrugResistant Tuberculosis (MDR-TB) treatment and for 6 months after stopping TMC207treatment, or if they are non-heterosexually active or willing to practice sexualabstinence throughout MDR-TB treatment

• For Cohorts 1 and 2 only: Boys who engage in sexual activity that could lead topregnancy of the female partner must use at minimum a male condom throughout MDR-TBtreatment and for 3 months after stopping TMC207 treatment

• Participant must have confirmed or probable (clinically diagnosed or presumed)pulmonary and/or non-severe extrapulmonary MDR-TB, including pre-extensivelydrug-resistant TB (pre- extensively drug resistant [XDR]-TB) or XDR-TB infection,based on the case definitions of pediatric pulmonary and non-severe extrapulmonaryTB as described in the International (WHO) guidelines and in accordance with thelocal standard of care

• Participants must be starting the initial MDR-TB treatment at Day 1 or have startedan MDR-TB treatment within 12 weeks of Day 1 and are willing to modify it ifnecessary to an acceptable MDR-TB regimen for use with TMC207

• Participant must be willing to permanently discontinue RMP from at least 7 daysbefore the baseline visit

• Participant or legally acceptable representative must consent/assent to humanImmunodeficiency virus (HIV) testing of the participant. The mother must alsoconsent to testing of her own HIV status, if the potential participant is a childaged <2 years, or if the participant is >= 2 years old and being breastfed or wasbreastfed within the last 8 weeks before screening, unless the mother had HIV testperformed within 1 month prior to screening and documentation of HIV status can beprovided. When documented HIV-positive status is available prior to screening forparticipants in Cohort 4 or their mother, HIV testing for the participant and motheris not required

Exclusion Criteria:

• Participant has a clinically significant active medical condition or the presence ofany concomitant severe illness or rapidly deteriorating health condition, includingimmune deficiency (except HIV infection), which in the opinion of the investigatorwould prevent appropriate participation in the study, or that would makeimplementation of the protocol or interpretation of the study results difficult, orotherwise make the subject a poor candidate for a clinical study

• Participant is a girl who is pregnant, or breast-feeding, or planning to becomepregnant while enrolled in this study or within 6 months after stopping TMC207treatment

• Participant has known or presumed forms of extrapulmonary TB, other than:Lymphadenopathy (peripheral nodes or isolated mediastinal mass without significantairway compression); Pleural effusion or pleural fibrotic lesions

• Participant has a significant cardiac arrhythmia that requires medication or riskfactors for Torsade de Pointes, example heart failure, hypokalemia, known personalor family history of Long QT Syndrome, and untreated hypothyroidism